Ardelyx (ARDX) Stock Forecast & Price Target

Compare

1,790 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ARDX Analyst Ratings

Strong Buy

4 Buy

1 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Ardelyx

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ARDX Stock 12 Month Forecast

Average Price Target

$11.00

▲(91.64% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Ardelyx in the last 3 months. The average price target is $11.00 with a high forecast of $14.00 and a low forecast of $10.00. The average price target represents a 91.64% change from the last price of $5.74.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","15":"$15","5.25":"$5.25","8.5":"$8.5","11.75":"$11.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5.25,8.5,11.75,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.06,6.67076923076923,7.281538461538461,7.892307692307693,8.503076923076923,9.113846153846154,9.724615384615385,10.335384615384616,10.946153846153846,11.556923076923077,12.167692307692308,12.778461538461539,13.389230769230771,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.06,6.4399999999999995,6.819999999999999,7.199999999999999,7.58,7.959999999999999,8.34,8.719999999999999,9.1,9.48,9.86,10.239999999999998,10.620000000000001,{"y":11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.06,6.363076923076923,6.666153846153846,6.969230769230769,7.272307692307692,7.575384615384616,7.878461538461538,8.181538461538462,8.484615384615385,8.787692307692307,9.090769230769231,9.393846153846154,9.696923076923078,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.06,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$14.00

Average Price Target$11.00

Lowest Price Target$10.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Julian Harrison

BTIG

$14

Buy

143.90%

Upside

Reiterated

11/10/25

Analysts' Top Healthcare Picks: Harrow Health (HROW), Ardelyx (ARDX)

Allison Bratzel

Piper Sandler

$9→$10

Hold

74.22%

Upside

Reiterated

11/04/25

Ardelyx price target raised to $10 from $9 at Piper SandlerArdelyx price target raised to $10 from $9 at Piper Sandler

Yigal Nochomovitz

Citi

$10→$11

Buy

91.64%

Upside

Reiterated

11/03/25

Ardelyx price target raised to $11 from $10 at CitiArdelyx price target raised to $11 from $10 at Citi

Joseph Thome

TD Cowen

$9→$10

Buy

74.22%

Upside

Reiterated

10/31/25

Ardelyx's Strong Market Performance and Growth Potential Justify Buy Rating and Raised Price Target

Matthew Caufield

H.C. Wainwright

$10

Buy

74.22%

Upside

Reiterated

10/31/25

Ardelyx's Strategic Growth and Pipeline Potential Justify Buy RatingValuation and Risks. We reiterate our Buy rating and $10 price target. Our $10 price target is based on an equally-weighted composite of: (a) $9.18 per share, as a 25x multiple of taxed and diluted 2035 EPS of $1.28 discounted back to and (b) an NPV discounted cash flow between 2025-2035 of $10.84 per share, with a discount rate of 13% and growth rate of 1%. These assumptions are in-line with the expected P/E multiple and discount rates of an early commercial-stage biopharmaceutical company.

Christopher Raymond

Raymond James

$14

Buy

143.90%

Upside

Reiterated

09/26/25

Ardelyx (ARDX) Gets a Buy from Raymond James

Louise Chen

Scotiabank

$15

Buy

161.32%

Upside

Reiterated

08/05/25

Scotiabank Sticks to Its Buy Rating for Ardelyx (ARDX)

Roanna Ruiz

Leerink Partners

$10→$11

Buy

91.64%

Upside

Reiterated

08/05/25

Ardelyx's Strong Financial Performance and Strategic Positioning Drive Buy Rating and Increased Price Target

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$13→$14

Buy

143.90%

Upside

Reiterated

08/05/25

Wedbush Sticks to Their Buy Rating for Ardelyx (ARDX)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$11→$13

Buy

126.48%

Upside

Reiterated

07/15/25

Wedbush Sticks to Its Buy Rating for Ardelyx (ARDX)

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Reiterated

07/07/25

Cantor Fitzgerald reiterates Overweight Rating on Ardelyx, Inc (ARDX)Cantor Fitzgerald analyst Louis Chen reiterated an Overweight rating on Ardelyx, Inc (NASDAQ: ARDX).

Dennis Ding

Jefferies

Buy

39.37%

Upside

Reiterated

07/02/25

Ardelyx's Legal Battle and Potential Growth: Analyst Recommends Buy Amidst Xphozah's CMS Appeal

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$11

Buy

91.64%

Upside

Reiterated

05/02/25

Aydin Huseynov

Ladenburg Thalmann & Co.

$13.5→$11

Buy

91.64%

Upside

Reiterated

03/07/25

Ardelyx price target lowered to $11 from $13.50 at LadenburgArdelyx price target lowered to $11 from $13.50 at Ladenburg

Ed Arce

Westpark Capital

$5.5

Hold

-4.18%

Downside

Reiterated

02/20/25

Analysts Offer Insights on Healthcare Companies: Evolent Health (NYSE: EVH), Benitec Biopharma (NASDAQ: BNTC) and Ardelyx (NASDAQ: ARDX)We maintain our Neutral rating for ARDX shares as we project a low single-digit quarterly growth for XPHOZAH in 2025 while we await additional clarity on its outlook, for both near-term and long-term. Maintain Neutral with $5.50 PT.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Julian Harrison

BTIG

$14

Buy

143.90%

Upside

Reiterated

11/10/25

Analysts' Top Healthcare Picks: Harrow Health (HROW), Ardelyx (ARDX)

Allison Bratzel

Piper Sandler

$9→$10

Hold

74.22%

Upside

Reiterated

11/04/25

Ardelyx price target raised to $10 from $9 at Piper SandlerArdelyx price target raised to $10 from $9 at Piper Sandler

Yigal Nochomovitz

Citi

$10→$11

Buy

91.64%

Upside

Reiterated

11/03/25

Ardelyx price target raised to $11 from $10 at CitiArdelyx price target raised to $11 from $10 at Citi

Joseph Thome

TD Cowen

$9→$10

Buy

74.22%

Upside

Reiterated

10/31/25

Ardelyx's Strong Market Performance and Growth Potential Justify Buy Rating and Raised Price Target

Matthew Caufield

H.C. Wainwright

$10

Buy

74.22%

Upside

Reiterated

10/31/25

Christopher Raymond

Raymond James

$14

Buy

143.90%

Upside

Reiterated

09/26/25

Ardelyx (ARDX) Gets a Buy from Raymond James

Louise Chen

Scotiabank

$15

Buy

161.32%

Upside

Reiterated

08/05/25

Scotiabank Sticks to Its Buy Rating for Ardelyx (ARDX)

Roanna Ruiz

Leerink Partners

$10→$11

Buy

91.64%

Upside

Reiterated

08/05/25

Ardelyx's Strong Financial Performance and Strategic Positioning Drive Buy Rating and Increased Price Target

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$13→$14

Buy

143.90%

Upside

Reiterated

08/05/25

Wedbush Sticks to Their Buy Rating for Ardelyx (ARDX)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$11→$13

Buy

126.48%

Upside

Reiterated

07/15/25

Wedbush Sticks to Its Buy Rating for Ardelyx (ARDX)

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Reiterated

07/07/25

Cantor Fitzgerald reiterates Overweight Rating on Ardelyx, Inc (ARDX)Cantor Fitzgerald analyst Louis Chen reiterated an Overweight rating on Ardelyx, Inc (NASDAQ: ARDX).

Dennis Ding

Jefferies

Buy

39.37%

Upside

Reiterated

07/02/25

Ardelyx's Legal Battle and Potential Growth: Analyst Recommends Buy Amidst Xphozah's CMS Appeal

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$11

Buy

91.64%

Upside

Reiterated

05/02/25

Aydin Huseynov

Ladenburg Thalmann & Co.

$13.5→$11

Buy

91.64%

Upside

Reiterated

03/07/25

Ardelyx price target lowered to $11 from $13.50 at LadenburgArdelyx price target lowered to $11 from $13.50 at Ladenburg

Ed Arce

Westpark Capital

$5.5

Hold

-4.18%

Downside

Reiterated

02/20/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ardelyx

1 Month

xxx

Success Rate

10/16 ratings generated profit

Average Return

+5.36%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +5.36% per trade.

3 Months

xxx

Success Rate

9/17 ratings generated profit

Average Return

+21.25%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +21.25% per trade.

1 Year

Christopher RaymondRaymond James

Success Rate

9/17 ratings generated profit

Average Return

+27.03%

reiterated a buy rating 3 months ago

Copying Christopher Raymond's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of +27.03% per trade.

2 Years

xxx

Success Rate

9/16 ratings generated profit

Average Return

+98.91%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 56.25% of your transactions generating a profit, with an average return of +98.91% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARDX Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ARDX has received 9 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. ARDX average Analyst price target in the past 3 months is 11.00.

Each month's total comprises the sum of three months' worth of ratings.

ARDX Financial Forecast

ARDX Earnings Forecast

Next quarter’s earnings estimate for ARDX is $0.02 with a range of -$0.02 to $0.06. The previous quarter’s EPS was $0.00. ARDX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ARDX has Performed in-line its overall industry.

ARDX Sales Forecast

Next quarter’s sales forecast for ARDX is $119.36M with a range of $115.80M to $121.99M. The previous quarter’s sales results were $110.33M. ARDX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ARDX has Performed in-line its overall industry.

ARDX Stock Forecast FAQ

What is ARDX’s average 12-month price target, according to analysts?

Based on analyst ratings, Ardelyx’s 12-month average price target is 11.00.

What is ARDX’s upside potential, based on the analysts’ average price target?

Ardelyx has 91.64% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ARDX a Buy, Sell or Hold?

Ardelyx has a consensus rating of Strong Buy which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.

What is Ardelyx’s price target?

The average price target for Ardelyx is 11.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $14.00 ,the lowest forecast is $10.00. The average price target represents 91.64% Increase from the current price of $5.74.

What do analysts say about Ardelyx?

Ardelyx’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of ARDX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Ardelyx (ARDX) Stock Forecast & Price Target

ARDX Analyst Ratings

ARDX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ardelyx

ARDX Analyst Recommendation Trends

ARDX Financial Forecast

ARDX Earnings Forecast

ARDX Sales Forecast

ARDX Stock Forecast FAQ

Detailed List of Analyst Forecasts